ArticleArteriosclerosis, thrombosis, and vascular biology2014
Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- A systematic review evaluating imaging techniques to determine chronicity of deep vein thrombosis.Phlebology · 2026Pooled it
- Molecular MRI of Collagen Enables Evaluation of Fibrosis and Therapeutic Response in Venous Thrombosis.Circulation. Cardiovascular imaging · 2026Article
- Multiparametric Contrast-Free MRI Successfully Identifies Venous Thrombus Responsive to Lytic Therapy: From Mice to Humans.Circulation. Cardiovascular imaging · 2025Article
- Experimental multiparametric magnetic resonance imaging characterization of iliocaval venous thrombosis pathological changes.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- Immune cell-mediated venous thrombus resolution.Research and practice in thrombosis and haemostasis · 2023Review
- Gadofosveset-Trinatrium-Enhanced MR Angiography and MR Venography in the Diagnosis of Venous Thromboembolic Disease: A Single-Center Cohort Study.Diseases (Basel, Switzerland) · 2022Article
- A fibrin targeted molecular imaging evaluation of microvascular no-reflow in acute ischemic stroke.Brain and behavior · 2022Article
- Thrombus Structural Composition in Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects.Circulation · 2021Article
- Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases.Antioxidants & redox signaling · 2019Review
- Post-ischaemic exuberant left ventricular mass: thrombus vs. tumour-case report.European heart journal. Case reports · 2018Article
- State-of-the-Art Imaging for the Evaluation of Pulmonary Embolism.Current treatment options in cardiovascular medicine · 2018Review
- Imaging Tropoelastin in Atherosclerosis.Circulation. Cardiovascular imaging · 2018Article
- In Vivo Molecular Characterization of Abdominal Aortic Aneurysms Using Fibrin-Specific Magnetic Resonance Imaging.Journal of the American Heart Association · 2018Article
- Simultaneous bright- and black-blood whole-heart MRI for noncontrast enhanced coronary lumen and thrombus visualization.Magnetic resonance in medicine · 2018Article
- Peptide-based fibrin-targeting probes for thrombus imaging.Dalton transactions (Cambridge, England : 2003) · 2017Review
- Metabolic and Molecular Imaging of Atherosclerosis and Venous Thromboembolism.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Fibrinogen and Fibrin in Hemostasis and Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2017Review
- FeInternational journal of nanomedicine · 2017Article
- Molecular magnetic resonance imaging of atherosclerotic vessel wall disease.European radiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveDeep venous thrombosis is a major health problem. Thrombolytic therapies are effective in recanalizing the veins and preventing post-thrombotic complications, but there is no consensus on selection criteria. The aim of this study was to investigate a fibrin-specific MRI contrast agent (EP-2104R) for the accurate quantification of thrombus' fibrin content in vivo and for the identification of thrombus suitable for thrombolysis. APPROACH AND
resultsVenous thrombosis was induced in the inferior vena cava of 8- to 10-week-old male BALB/C mice and MRI performed 2, 4, 7, 10, 14, and 21 days later. Eighteen mice were scanned at each time point pre and 2 hours post injection of EP-2104R (8.0 μmol/kg) with 12 mice at each time point used to correlate fibrin contrast uptake with thrombus' histological stage and fibrin content. Six mice at each time point were immediately subjected to intravascular thrombolytic therapy (10 mg/kg of tissue-type plasminogen activator). Mice were imaged to assess response to lytic therapy 24 hours after thrombolytic treatment. Two mice at each time point were scanned post injection of 0.2 mmol/kg of Gd-DTPA (gadolinium with diethylenetriaminepentacetate, Magnevist, Schering AG, Berlin, Germany) for control purpose. Contrast uptake was correlated positively with the fibrin content of the thrombus measured by Western blotting (R(2)=0.889; P<0.001). Thrombus relaxation rate (R1) post contrast and the change in visualized thrombus size on late gadolinium enhancement inversion recovery MRI pre-EP-2104R and post-EP-2104R injection were the best predictors for successful thrombolysis (area under the curve, 0.989 [95% confidence interval, 0.97-1.00] and 0.994 [95% confidence interval, 0.98-1.00] respectively).
conclusionsMRI with a fibrin-specific contrast agent accurately estimates thrombus fibrin content in vivo and identifies thrombi that are amenable for thrombolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.